Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol UFT/Leucovorin Approval May Await Analysis Of Uracil Contribution

Executive Summary

FDA's approval decision for Bristol's UFT for treatment of metastatic colorectal cancer may hinge on the contribution of the product's uracil component to the efficacy of the combination.

You may also be interested in...



House Committee Watching Genasense; Show Of Force During FDA Review

The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense

House Committee Watching Genasense; Show Of Force During FDA Review

The House Energy & Commerce Committee is keeping a close watch on FDA's handling of the application for Aventis/Genta's Genasense

Bristol To Focus On Paraplatin For Oncology Growth; UFT Review Delayed

Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.

UsernamePublicRestriction

Register

ID1130879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel